Further validation of the efficacy of mesenchymal stem cell infusions for reducing mortality in COVID-19 patients with ARDS

Ashok K. Shetty; Padmashri A. Shetty; Gabriele Zanirati; Kunlin Jin

doi:10.1038/s41536-021-00161-z

npj Regenerative Medicine (Sep 2021)

Further validation of the efficacy of mesenchymal stem cell infusions for reducing mortality in COVID-19 patients with ARDS

Ashok K. Shetty,
Padmashri A. Shetty,
Gabriele Zanirati,
Kunlin Jin

Affiliations

Ashok K. Shetty: Institute for Regenerative Medicine, Department of Molecular and Cellular Medicine, Texas A&M University College of Medicine
Padmashri A. Shetty: Ramaiah Medical College
Gabriele Zanirati: Brain Institute of Rio Grande do Sul (BraIns), Pontifical Catholic University of Rio Grande do Sul (PUCRS)
Kunlin Jin: Department of Pharmacology and Neuroscience, University of North Texas Health Science Center Fort Worth

DOI: https://doi.org/10.1038/s41536-021-00161-z
Journal volume & issue: Vol. 6, no. 1
pp. 1 – 3

Abstract

Read online

Recent double-blind, randomized, controlled trials reported that human umbilical cord-derived mesenchymal stem cell (MSC) infusions in COVID-19 patients with acute respiratory distress syndrome (ARDS) could diminish cytokine storm and lung damage. While these outcomes are significant, additional phase II/III trials are required to validate the efficacy of MSCs to improve the survival of COVID-19 patients with ARDS. Future studies also need to assess the efficacy of MSCs to prevent long COVID.

Published in npj Regenerative Medicine

ISSN: 2057-3995 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Medicine
Website: https://www.nature.com/npjregenmed/

About the journal